Medexus Pharmaceuticals Inc. (MEDXF) Stock: Price, Forecast & Analyst Target
Medexus Pharmaceuticals Inc. (MEDXF) — price $3.90 (-6.47%), as of the Nov 19, 2026 trading session; market cap $123M.
Educational signal · not a buy or sell recommendation · How to read this
Medexus Pharmaceuticals Inc. · MEDXF
Medexus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on oncology, hematology, rheumatology, auto-immune diseases, and allergy. Their portfolio includes products like Rasuvo, Metoject, and IXINITY, distributed in Canada and the United States.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $3.90 | |
| Change on the day | -6.47% | |
| Market capitalisation | $123M | — |
| Shares traded on the day | 13.7K |
Price & events
Other perspectives
Council score for Medexus Pharmaceuticals (MEDXF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Medexus Pharmaceuticals (MEDXF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Medexus Pharmaceuticals Inc. (MEDXF) is the company analyzed here. It employs 90 people. In Q1 FY2027 it reported revenue of $28M and net income of $530,185. The market values it at $123M.
What do the latest results show for Medexus Pharmaceuticals (MEDXF)?
Short answer · as of
The most recent reported quarter, Q1 FY2027, carried revenue of $28M. Against analyst estimates the company has EPS beat 5 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2027 | $28M | $530,185 | $0.02 (diluted) |
| Q4 FY2026 | $25M | -$3M | -$0.08 (diluted) |
| Q3 FY2026 | $25M | $80,000 | $0.0025 (diluted) |
| Q2 FY2026 | $25M | -$315,000 | -$0.01 (diluted) |
What are the financial strengths and risks for Medexus Pharmaceuticals (MEDXF)?
Short answer · as of
The distress and quality screens read Altman Z 1.47 · Piotroski F 5. Trailing ratios: ROE -4.7% · ROA -1.7% · current ratio 1.30 · earnings yield -2.0% · free-cash-flow yield -1.0%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 1.47 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-4.7%) — the business is not currently generating profit on shareholder capital.
What should you watch next at Medexus Pharmaceuticals (MEDXF)?
Short answer · as of
Current published price targets run low $7.00 · high $7.00 · consensus $7.00 · median $7.00 against a quoted price of $3.90 (as of Nov 19, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $7.00 – $7.00
- Consensus target
- $7.00
- Median target
- $7.00
Consensus record · Captured .
Measured against a quoted price of $3.90 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MEDXF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported MEDXF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About MEDXF
These answers are editorial: 1 of these 8 answers is drawn from the MEDXF research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is MEDXF a good stock to buy?
Stock Expert AI does not rate MEDXF buy, sell or hold. Medexus Pharmaceuticals Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the MEDXF stock price today?
The last price recorded for Medexus Pharmaceuticals Inc. (MEDXF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MEDXF price target?
The analyst consensus price target for Medexus Pharmaceuticals Inc. (MEDXF), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What do analysts say about MEDXF stock?
Investors should conduct their own due diligence and consider the company's financial performance, growth opportunities, and risk factors before making an investment decision. Key metrics to monitor include revenue growth, gross margin, profitability, and cash flow.
What are the key factors to evaluate for MEDXF?
Evaluate MEDXF on fundamentals, analyst consensus, and risk factors. To weigh it, read the analyst view under Analyst targets & estimates on this page. This can provide access to new technologies, expertise, or markets, accelerating its growth and reducing its financial risk. Not financial advice.
How frequently does MEDXF data refresh on this page?
MEDXF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven MEDXF's recent stock price performance?
Medexus Pharmaceuticals Inc. (MEDXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product portfolio targeting niche therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MEDXF overvalued or undervalued right now?
Medexus Pharmaceuticals Inc. (MEDXF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 16 figures on this page — 12 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com